Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.58 |
| ▸ | FOLH1 | Q04609 | 7/20 | 0.53 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.49 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.49 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.49 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.49 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.49 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.49 |
| ▸ | CASP3 | P42574 | 2/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP2 | P42575 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31433227 | 0.86 | TDP1 (0.59) | TDP1CAPN1FOLH1PSEN1PSEN2 | |
| SCHEMBL31433328 | 0.80 | TDP1 (0.75) | TDP1CAPN1FOLH1CNR1 | |
| SCHEMBL29439931 | 0.79 | TDP1 (0.73) | TDP1CAPN1FOLH1CASP3CASP1 | |
| SCHEMBL24858374 | 0.79 | TDP1 (0.73) | TDP1CAPN1FOLH1CASP3CASP1 | |
| SCHEMBL9807479 | 0.78 | TDP1 (0.77) | TDP1CAPN1FOLH1CNR1 | |
| SCHEMBL31332171 | 0.78 | CAPN1 (0.62) | TDP1CAPN1FOLH1 | |
| SCHEMBL29439904 | 0.77 | TDP1 (0.75) | TDP1CAPN1FOLH1CNR1 | |
| SCHEMBL29928558 | 0.77 | TDP1 (0.75) | TDP1CAPN1FOLH1 | |
| SCHEMBL13311852 | 0.77 | TDP1 (0.55) | TDP1CAPN1FOLH1PSEN1PSEN2 | |
| SCHEMBL13367527 | 0.77 | TDP1 (0.80) | TDP1CAPN1FOLH1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | CALICO LIFE SCIENCES LLC (US) | 2025-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | MICA, CD74, HLA-DRB1 | TDP1 4357/4885CAPN1 3160/4885FOLH1 2388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.